The Latest Cardiac and Vascular News
JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel: “I am very pleased to bring you an update on […]
October 19, 2023 Sustainability roadmap addresses opportunities to reduce carbon emissions in patient throughput, technology use, and use of consumables Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital – […]
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardio Flow, Inc., a privately held medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), today announced it recently received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s FreedomFlow Orbital Atherectomy Peripheral Platform. “Critical Limb Ischemia: Volume 1. […]
DEERFIELD, Ill. & NEW YORK–(BUSINESS WIRE)–Walgreens and the Cardiovascular Research Foundation (CRF) today announced a collaboration to drive forward the PREVUE-VALVE study, a groundbreaking population-based clinical trial that aims to quantify the prevalence of valvular heart disease (VHD) among older Americans and pave the way for the development of new […]
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the […]
NOVATO, Calif, Oct. 17, 2023 (GLOBE NEWSWIRE) — Cyclarity Therapeutics, Inc. (https://cyclaritytx.com), today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases. The Board includes the internationally recognized, […]
ABBOTT PARK, Ill., Oct. 18, 2023 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023. Third-quarter GAAP diluted EPS of $0.82 and adjusted diluted EPS of $1.14, which excludes specified items. Abbott narrowed its full-year 2023 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.14 to $3.18 and […]
WILMINGTON, N.C., Oct. 17, 2023 /PRNewswire/ — Alcami Corporation (“Alcami”), a leading contract development and manufacturing organization (CDMO), today welcomed the recent announcement by Nectero Medical that they have received clearance from the U.S. Food and Drug Administration of their IND application to initiate Phase II/III trial of the Nectero Endovascular Aneurysm […]
BRAINTREE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces the successful initial outcomes of using the LIBERTY Robotic Surgical System in its pivotal pre-clinical study. The pivotal study was conducted by three leading interventional radiologists that utilized […]
TAMPA, Fla.–(BUSINESS WIRE)–Praxis Medical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the EndoCore EBUS-TBNA fine needle biopsy device. “We are excited by the implications of how this device could progress the standard of care. Improving EBUS-TBNA sensitivity, diagnostic yield, and ancillary testing capabilities […]
